I AM ALS Patient-Centric Trial Design (PaCTD) Rating for MediciNova's Ibudilast

I AM ALS Patient-Centric Trial Design (PaCTD)		
Manufacturer	MediciNova	
Drug	**Ibudilast (NCT04057898)**	Rating
Open Label Extension Rating: 0 if not offered, .5 or 1 depending on if announced/implemented, how the OLE is structured, looking at length of time, amount of patient data collected that can help in the approval process, etc.	6 mo OLE included in protocol per clinicaltrials.gov. Duration should match blinded treatment phase	0.5
Minimize placebo usage Rating: 0, .5 or 1 depending on how progressive design is. Are the odds of receiving placebo less than 50%? For example the Healy Platform trial only randomizes 25% of participants into the shared placebo control and received a score of 1. Traditional 50/50 randomization gets a 0 score.	Traditional 1:1 Randomization	0
Expanded Access Program A side by side Intermediate (or larger) Rating: 0 if not offered, .25 proposed, .5 filed with FDA, .75 approved by FDA, 1 implemented. Other considerations: number of slots, time length and amount of patient data collected that can help in the approval process, or, once drug is approved, to help convince payors to cover all, policy posted on co. website	Not accepting requests for EAP	0
Part 1 Total		0.5
Part 1 Rating-Seats at the Table		0.1
A trial is awarded a rating of 0-1.0 depending on whether it incorporates design elements that may increase the chance of producing definitive trial results and advance the science of clinical trials in ALS. The following list provides examples but is not exhaustive. - Consideration of disease heterogeneity such as using a predictive algorithm for trial inclusion or a crossover design - Investigation of potentially regulatory grade biomarkers such as neurofilament light or digital biomarkers such as accelerometers. - Independent unblinded review panel for interim efficacy check-ins if warranted	No publicly available evidence of novel trial design	0
Part 2 Total		0
Part 2 Rating-Advancing Science Quickly		0

Minimize Use of Run-In Observation Period and Washout Period – Rating: 0. .5, 1 depending how accommodative the trial with patient friendly features like no run in period	Pre-trial screening takes approximately 1 month	1
Use of novel methods: wearables, telemedicine visits, financial reimbursement Rating: 0, .5, 1 depending how accommodative the trial design is to patient participation such as use of patient friendly features like travel reimbursement for patient and caregiver, home collection of patient data during the trial.	MedACT program helps to remove barriers to participation by providing financial and other support as needed	1
Part 3 Total		2
Part 3 Rating-Patient-Friendly		0.1
Total Rating		0.2
x 5		1
I AM ALS PaCTD 5-Star Rating:		**1-Star**